• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性冠状动脉综合征患者的肾功能不全、冠状动脉病变复杂性及不良心血管结局

Renal Dysfunction, Coronary Artery Lesion Complexity, and Adverse Cardiovascular Outcomes in Patients With Acute Coronary Syndrome.

作者信息

Chen Qiang, Li Yike, Yang Siqi, He Haoming, Xie Yingying, Wang Wei, Wang Long, Gao Yanxiang, Cai Lin, Xiong Shiqiang, Zheng Jingang

机构信息

Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 100029 Beijing, China.

Department of Cardiology, China-Japan Friendship Hospital, 100029 Beijing, China.

出版信息

Rev Cardiovasc Med. 2025 Jul 23;26(7):38389. doi: 10.31083/RCM38389. eCollection 2025 Jul.

DOI:10.31083/RCM38389
PMID:40776972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12326429/
Abstract

BACKGROUND

Renal dysfunction is linked to both the complexity of coronary artery lesions and the prognosis of acute coronary syndrome (ACS). However, the nature of this intricate relationship remains unclear. Therefore, this study aimed to investigate the mechanisms through which coronary lesion complexity mediates the association between renal dysfunction and adverse cardiovascular outcomes in patients with ACS.

METHODS

This analysis included 1400 ACS patients who underwent percutaneous coronary intervention (PCI). Renal function was assessed using the estimated glomerular filtration rate (eGFR), calculated according to the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which incorporates both creatinine and cystatin C. Coronary lesion complexity was evaluated using the baseline SYNTAX score (bSS). The associations among eGFR, bSS, and major adverse cardiovascular events (MACEs) were examined using survival analysis, restricted cubic spline (RCS) analysis, and mediation analysis.

RESULTS

A total of 229 MACEs (16.4%) occurred over a median follow-up of 31.03 (27.34, 35.06) months, including 99 all-cause deaths (7.0%), 41 myocardial infarctions (2.9%), and 123 unplanned revascularizations (8.9%). After multivariate adjustment, both the eGFR and bSS significantly predicted MACEs across the total population and various subgroups. Mediation analysis showed that bSS mediated 16.49%, 14.76%, 12.87%, and 11.95% of the correlation between eGFR and MACEs in different adjusted models.

CONCLUSION

The relationship between renal dysfunction and MACEs in ACS patients is partially mediated by coronary lesion complexity. This finding underscores the importance of integrating kidney function assessments with coronary anatomical evaluations to develop individualized risk stratification strategies.

摘要

背景

肾功能不全与冠状动脉病变的复杂性以及急性冠状动脉综合征(ACS)的预后均相关。然而,这种复杂关系的本质仍不清楚。因此,本研究旨在探讨冠状动脉病变复杂性介导ACS患者肾功能不全与不良心血管结局之间关联的机制。

方法

本分析纳入了1400例接受经皮冠状动脉介入治疗(PCI)的ACS患者。使用根据2021年慢性肾脏病流行病学协作组(CKD-EPI)方程计算的估计肾小球滤过率(eGFR)评估肾功能,该方程纳入了肌酐和胱抑素C。使用基线SYNTAX评分(bSS)评估冠状动脉病变复杂性。采用生存分析、限制性立方样条(RCS)分析和中介分析研究eGFR、bSS与主要不良心血管事件(MACE)之间的关联。

结果

在中位随访31.03(27.34,35.06)个月期间,共发生229例MACE(16.4%),包括99例全因死亡(7.0%)、41例心肌梗死(2.9%)和123例非计划血管重建(8.9%)。多变量调整后,eGFR和bSS在总体人群及各个亚组中均显著预测MACE。中介分析显示,在不同调整模型中,bSS介导了eGFR与MACE之间相关性的16.49%、14.76%、12.87%和11.95%。

结论

ACS患者肾功能不全与MACE之间的关系部分由冠状动脉病变复杂性介导。这一发现强调了将肾功能评估与冠状动脉解剖评估相结合以制定个体化风险分层策略的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/61156f52c450/2153-8174-26-7-38389-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/c910b01d657e/2153-8174-26-7-38389-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/d05e401bbad0/2153-8174-26-7-38389-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/16e921a44ae3/2153-8174-26-7-38389-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/7812fe9c6209/2153-8174-26-7-38389-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/61156f52c450/2153-8174-26-7-38389-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/c910b01d657e/2153-8174-26-7-38389-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/d05e401bbad0/2153-8174-26-7-38389-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/16e921a44ae3/2153-8174-26-7-38389-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/7812fe9c6209/2153-8174-26-7-38389-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bd/12326429/61156f52c450/2153-8174-26-7-38389-g5.jpg

相似文献

1
Renal Dysfunction, Coronary Artery Lesion Complexity, and Adverse Cardiovascular Outcomes in Patients With Acute Coronary Syndrome.急性冠状动脉综合征患者的肾功能不全、冠状动脉病变复杂性及不良心血管结局
Rev Cardiovasc Med. 2025 Jul 23;26(7):38389. doi: 10.31083/RCM38389. eCollection 2025 Jul.
2
Insulin resistance, coronary artery lesion complexity and adverse cardiovascular outcomes in patients with acute coronary syndrome.胰岛素抵抗与急性冠状动脉综合征患者冠状动脉病变复杂性及不良心血管转归的关系。
Cardiovasc Diabetol. 2024 May 16;23(1):172. doi: 10.1186/s12933-024-02276-1.
3
Impact of the 2021 Chronic Kidney Disease Epidemiology Collaboration glomerular filtration rate estimating equation on risk of healthcare utilization for hospitalizations for cardiovascular and kidney disease.2021年慢性肾脏病流行病学协作组肾小球滤过率估算方程对心血管疾病和肾脏疾病住院医疗利用风险的影响
Nephron. 2025 Aug 4:1-20. doi: 10.1159/000547627.
4
Indobufen versus aspirin after percutaneous coronary intervention in elderly patients with acute coronary syndrome.吲哚布芬与阿司匹林用于老年急性冠状动脉综合征患者经皮冠状动脉介入治疗后的比较
BMC Cardiovasc Disord. 2025 Jul 7;25(1):495. doi: 10.1186/s12872-025-04843-0.
5
Evaluation of the Atherogenic Index of Plasma in the Prognostic Value of Ischemic Heart Failure Post-Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后缺血性心力衰竭预后价值中血浆致动脉粥样硬化指数的评估
Rev Cardiovasc Med. 2025 Jun 30;26(6):33470. doi: 10.31083/RCM33470. eCollection 2025 Jun.
6
Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.慢性肾脏病与替尔泊肽对射血分数保留的肥胖心力衰竭患者的影响:SUMMIT试验
J Am Coll Cardiol. 2025 May 13;85(18):1721-1735. doi: 10.1016/j.jacc.2025.03.009. Epub 2025 Mar 31.
7
Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.睾酮性别肯定激素疗法对出生时被指定为女性的跨性别者肾功能的影响:一项荟萃分析。
Front Endocrinol (Lausanne). 2025 Jun 12;16:1537838. doi: 10.3389/fendo.2025.1537838. eCollection 2025.
8
Adoption of CKD-EPI (2021) for Glomerular Filtration Rate Estimation: Implications for UK Practice.采用CKD-EPI(2021)估算肾小球滤过率:对英国实践的影响。
Nephron. 2025;149(3):133-148. doi: 10.1159/000541689. Epub 2024 Sep 28.
9
Does diabetes status modify the association between the triglyceride-glucose index and major adverse cardiovascular events in patients with coronary heart disease? A systematic review and meta-analysis of longitudinal cohort studies.糖尿病状态是否会改变冠心病患者甘油三酯-葡萄糖指数与主要不良心血管事件之间的关联?一项纵向队列研究的系统评价和荟萃分析。
Cardiovasc Diabetol. 2025 Aug 4;24(1):317. doi: 10.1186/s12933-025-02890-7.
10
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.

本文引用的文献

1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
2
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南
Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
3
Increased Subclinical Coronary Artery Pathology in Type 2 Diabetes With Albuminuria.
2 型糖尿病伴白蛋白尿患者亚临床冠状动脉病变增加。
Diabetes. 2024 Mar 1;73(3):490-496. doi: 10.2337/db23-0529.
4
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.估计 2 型糖尿病合并白蛋白尿患者接受 SGLT2 抑制剂、GLP-1 受体激动剂和非甾体类 MRA 联合治疗与常规治疗相比的终生心血管、肾脏和死亡率获益。
Circulation. 2024 Feb 6;149(6):450-462. doi: 10.1161/CIRCULATIONAHA.123.067584. Epub 2023 Nov 12.
5
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association.心血管-肾脏-代谢健康:美国心脏协会的总统顾问报告
Circulation. 2023 Nov 14;148(20):1606-1635. doi: 10.1161/CIR.0000000000001184. Epub 2023 Oct 9.
6
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association.心血管-肾脏-代谢(CKM)综合征的科学证据和临床管理概要:美国心脏协会的科学声明
Circulation. 2023 Nov 14;148(20):1636-1664. doi: 10.1161/CIR.0000000000001186. Epub 2023 Oct 9.
7
Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era.迈向个性化心血管护理:全球急性冠状动脉事件注册研究3.0评分预示着人工智能时代的到来。
Eur Heart J. 2023 Nov 21;44(44):4615-4616. doi: 10.1093/eurheartj/ehad597.
8
Modification of the GRACE Risk Score for Risk Prediction in Patients With Acute Coronary Syndromes.GRACE 风险评分在急性冠状动脉综合征患者风险预测中的修正。
JAMA Cardiol. 2023 Oct 1;8(10):946-956. doi: 10.1001/jamacardio.2023.2741.
9
2023 ESC Guidelines for the management of acute coronary syndromes.2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
10
The cardio-renal-metabolic connection: a review of the evidence.心肾代谢关联:证据回顾。
Cardiovasc Diabetol. 2023 Jul 31;22(1):195. doi: 10.1186/s12933-023-01937-x.